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Neutrophils form the majority of circulating white blood cells and play a principle 
role in defending the body against invasions by microorganisms. Neutrophils 
engulf microorganisms into a phagosome where they kill them using reactive 
oxygen species and a range of antimicrobial proteins. Sepsis is described as a 
complicated clinical disorder that is generated from a dangerous host response to 
an infection. One of the main organisms responsible for causing infection in sepsis 
is Staphylococcus aureus.  
 Pro-inflammatory cytokines are elevated in patients with sepsis. These cytokines 
are also known to prime neutrophils and as a result, superoxide production is 
elevated in neutrophils. This may help to destroy the pathogen more rapidly.  The 
main aim of this study was to compare the ability of neutrophils to kill S. aureus in 
serum from healthy individuals to that in serum rich in inflammatory cytokines 
obtained from sepsis patients. To test the priming effect of sepsis serum, 
neutrophils were pre-incubated in either healthy or sepsis serum followed by 
stimulation with Formyl-methionyl-leucyl-phenylalanine. Cells incubated in sepsis 
serum followed by stimulation showed significantly increased superoxide 
production compared to cells incubated in healthy serum.  
S. aureus were pre-treated in either serum collected from healthy donors or serum 
from patients with sepsis and then incubated with neutrophils. A one-step 
neutrophil killing assay was used which gave the combined rate of phagocytosis 
and killing. I found that there was no significant differences in the rate of 
phagocytosis and killing of S. aureus by neutrophils in healthy and sepsis serum.  
Since neutrophils kill S. aureus mainly by an oxidative mechanism, the effect of 
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diphenylene iodonium, an inhibitor of flavoproteins such as NADPH oxidase, was 
checked to see if there was any difference in the mechanism of killing in sepsis 
serum. I found that the contribution of NADPH oxidase derived oxidants to killing 
was similar in healthy or sepsis serum.  
S. aureus have adapted many protective mechanisms in order to avoid being 
destroyed by neutrophils. A two-step killing assay that separate rates of killing and 
phagocytosis, was used to assess whether S. aureus collected from patients after 
antibiotic treatment were more resistant to neutrophil killing. The result showed 
no difference in the rate of neutrophil phagocytosis and killing of clinical isolates 
compared to the lab strain of S. aureus.  
Hypochlorous acid is a powerful oxidant used by neutrophils to kill invading 
microorganisms. It is known that S. aureus can survive within neutrophil, despite 
exposure to hypochlorous acid potentially by upregulation of survival genes. 
Pretreatment of S. aureus with a sub-lethal dose of hypochlorous acid did not 
protect bacteria from a subsequent dose of hypochlous acid. 
 
In conclusion I have tested neutrophil killing of S. aureus in normal healthy serum 
and serum from sepsis patients. The results show that even though there was 
increased superoxide production by neutrophils pre-treated in sepsis serum 
compared to healthy serum, the rate of phagocytosis and killing were the same. 
This suggests that pre-treatment of neutrophils with pro-inflammaotry cytokines 
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Table 1. Table of abbreviations 
Abbreviation Full name 
C3 complement component 3 
CGD chronic granulomatous disease 
COX-2 cycloocygenase 
fMLP Formyl-methionyl-leucyl-phenylalanine 
G-CSF or GCSF granulocyte colony-stimulating factor 
GTPase guanosine triphosphatase 
ICAM-1 intracellular adhesion molecule-1 
IFN γ interferon γ 
IgG immunoglobulin G 
IL-1Ra IL-1 receptor antagonist 
IL-1β interleukin 1 beta 
IL-2 interleukin-2 
iNOS induction of nitric oxide synthase 
LFA-1 lymphocyte function-associated antigen 1 
LPS lipopolysaccharide 
LTA lipoteichoic acid 
Mac-1 Macrophage-1 antigen 
MHC II major histocompatibility complex class II 
MIF macrophage migratory inhibitory factor 
MPO myeloperoxidase 
NADPH nicotinamide adenine dinucleotide phosphate 
NO nitric oxide 
PAMPs pathogen-associated molecular patterns 
PECAM-1 (also CD31) platelet endothelial cell adhesion molecule  
PGE2 prostaglandin E2 
PMN (or neutrophils) Polymorphonuclear leukocytes 
PRRs pattern recognition receptors 
ROS reactive oxidant species 
T-cell T lymphocytes 
TCR T-lymphocyte receptor 
Th1 T-helper 1 
TLRs toll-like receptors 
TNF tumour necrosis factor 
TSST-1 toxic shock syndrome toxin-1 
VCAM-1 vascular cell adhesion proteins 1 
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Section 1 – Introduction 
1.1 Neutrophils 
Polymorphonuclear leukocytes (PMN or neutrophils) form the majority of 
circulating white blood cells accounting for 50% to 70 % of all white blood cells in 
the body and play a principle role in defending the body against invasions by 
microorganisms. These fully differentiated cells are short-lived, and are well 
equipped to trigger and kill invading microorganisms as part of the innate immune 
response (1). Patients who suffer from diseases such as neutropenia, chronic 
granulomatous disease, or leukocyte adhesion deficiencies are especially 
susceptible to life-threatening bacterial and fungal infections (2). 
Neutrophils, like all immune cells, are produced in the bone marrow during the 
process of blood-cell-forming (hematopoiesis) at a rate of about 1011 per day and 
have the ability to amplify to 1012 per day in the course of an infection. Therefore, 
it is not surprising that approximately two thirds (55% to 60%) of the bone 
marrow is devoted to the generation of neutrophils (3). The formation of 
neutrophils is dependent on the responses of several cytokines, predominantly 
granulocyte colony-stimulating factor (G-CSF) (4). Hematopoietic stem cells are 
normally confined to cavities supplied by osteoblasts that are characterized by low 
blood flow and low oxygen tension, whereas stem cells that are actively dividing 
and are much more mature are closer to the vascular side of the bone marrow (4).  
Neutrophil maturation takes place in cavities within the microenvironment of the 
bone marrow before it migrates towards the venous sinuses. When myeloid 
precursors turn into mature neutrophils, they obtain the important features 
necessary for microbiocidal action. This includes acquisition of receptors for 
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signalling and phagocytosis, nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase proteins and granule components (5).  
As well as maturation, neutrophils also undergo morphological changes such as 
nuclear segmentation and increased sensitivity to chemotaxis responsiveness. This 
post-mitotic neutrophil maturation under basal condition usually takes 
approximately 6–8 days and once the mature neutrophils are discharged into the 
blood stream, they typically circulate with a half-life of approximately 6–8 hours 
(6).  
1.1.1 Neutrophil recruitment 
When neutrophils are released from the bone marrow, they then circulate into the 
vasculature and if required they move to the peripheral tissues, ready for 
activation. Immediate movement of neutrophils to peripheral tissues is essential 
for the innate immune response. Mobilization of neutrophils from bone marrow to 
the site of infection is a multi-step process that is receptor-mediated, and involves 
many chemo-attractants.  
The capability of neutrophils to migrate to an infection site is a fundamental part of 
the acute inflammatory response. When microorganisms in the body cause an 
infection they activate a chemotactic response involving release of chemokines. 
The range of chemokines required to recruit neutrophils depends on the virulence 
factors provided by the microorganism and on the signalling pathways that it 
activates (7). Neutrophil recruitment from the vasculature to the site of infection 
can be separated into four different steps: rolling adhesion, integrin activation, 
firm adhesion, and transmigration. When microorganisms such as bacteria invade 
the tissue, the products of the microorganism such as N-Formylmethionine-leucyl-
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phenylalanine (fMLP) and lipopolysaccharide (LPS) trigger the local residing 
macrophages and mast cells to secrete pro-inflammatory cytokines such as tumour 
necrosis factor (TNF) and interleukin 1 beta (IL-1β) which results in activation of 
local vascular endothelial cells. This leads to receptor-mediated adhesion of 
circulating neutrophils to the vascular endothelial cells (7).  
L-selectin is an adhesion molecule present on neutrophils which mediates the 
interaction of neutrophils to the endothelial cells. Stimulation of endothelial cells 
leads to temporary expression of the receptors E- and P-selectin that bind to L-
selectin. Subsequent interactions of neutrophil β2-integrins and intracellular 
adhesion molecule-1 (ICAM-1) on the endothelial cell causes a firm adhesion of the 
neutrophil to the endothelial cell (Figure 1). Then, several other neutrophil-
expressed surface molecules, such as clusters of differentiation molecules, CD31, 
CD54, CD39, and CD47 (8), (9) induce transmigration of into the site of infection. 
The tight junctions of the epithelial cells are unzipped by neutrophils that use 
other binding partners, such as platelet endothelial cell adhesion 
molecule (PECAM-1), better known as CD31, lymphocyte function-associated 
antigen 1 (LFA-1), and Macrophage-1 antigen (Mac-1), or better known as 
CD11b/CD18 (10) which are all involved in modulating neutrophil recruitment. As 
a result, the neutrophil is able to pass through the tight junctions. Finger-like 
projections on the apical side of the endothelial membrane are high in vascular cell 
adhesion proteins 1(VCAM-1) and (ICAM-1), which modulate trans-cellular 
migration by binding to neutrophils and guiding them through the cell (11).  
Once the neutrophils are out in the tissue, an increased transcriptional activity 
takes place in the bone marrow to produce and release them into the circulation. 
This activity is modulated by granulocyte-colony stimulating factor (G-
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CSF or GCSF), better known as colony-stimulating factor 3 (CSF 3). The neutrophil 
then initiates phagocytosis of the microorganism. After they have ingested the 
microorganism they may undergo apoptosis or NETosis. Apoptotic neutrophils are 
cleared by microphages (Figure 1). Even though it is well known that leukocytes 
travels paracellularly, evidence now supports that leukocytes use transcellular 
routes to pass right through endothelial calles (12) .  
 
 
Figure 1. Schematic view of neutrophil recruitment to the site of an infection from (4). Figure 
is described in the main text. 
 
1.1.2 Mechanism of neutrophil killing of microorganism 
Neutrophils play a principal role in protecting the host against microorganisms 
and removing pathogens by a process called phagocytosis. Recognition and 
binding of bacteria is the first step to establish phagocytosis, followed by 
internalization of the microorganism (9). Bacteria such as Staphylococcus aureus 
 
5 
(S. aureus) contain a diverse range of structures to help establish recognition by 
neutrophils. S. aureus molecules such as lipoteichoic acid (LTA) and peptidoglycan 
(PGN) (13) contain pathogen-associated molecular patterns (PAMPs) that cause 
interaction with receptors present on the neutrophil surfaces (9). In turn, 
neutrophils express pattern recognition receptors (PRRs) that include a large 
diversity of membrane-bound receptors such Toll-like receptors (TLRs) 1,2,4–10 
(14). These TLRs are able to identify highly conserved regions of bacterial 
products. Commonly, interaction of neutrophil PRRs and bacterial products 
activates a signal transduction pathway that eventually lengthens cell survival, 
enables adhesion and phagocytosis and up-regulates the release of cytokines, 
chemokines and reactive oxidant species (ROS) (15) and initiates degranulation 
(see 1.1.4 Degranulation). 
Neutrophil phagocytosis is efficiently enhanced if the invading microorganisms 
have been opsonized with host proteins and serum molecules such as antibodies 
and compliment. Specific immunoglobulin G (IgG) antibodies recognize microbial 
surface epitopes and attach to them. Neutrophils have receptors that specifically 
recognise the Fc-region of the antibody, thus pulling in the microorganism for 
ingestion (16) (see Figure 2).  
Microorganisms opsonized with complement proteins such as 
complement component 3b (C3b), are recognized by their specific receptors on the 
neutrophil and are eventually ingested into the cell. The physical process of 
phagocytosis is mainly caused by the ligation of the membrane-bound opsonin 
receptors, which causes alterations in the neutrophil cytoskeleton. Once a microbe 
is ingested by the neutrophil, actin microfilaments close to the receptor help the 
plasma membrane to circulate around the surface of the microbe until the 
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engulfment is complete. The microbe is then hidden away within the membrane-
bound vacuole, better known as a phagosome (16).  
 
Figure 2. Phagocytosis of S. aureus by a neutrophil from (16). 
 
1.1.3 NADPH oxidase and the oxidative burst  
Phagocytosis of the microbe induces an array of antimicrobial activity within the 
neutrophil phagosome. This activity generally comes from two predominant 
sources. First, superoxide radicals are produced and further ROS such as hydrogen 
peroxide and hypochlorous acid are generated (Figure 3) (15), (17). The second 
step is the release of granule proteins consisting of antimicrobial proteins, lytic 
enzymes, and peptides into the phagosome (18). The neutrophil generates 
microbicidal oxidants as a result of the activation of the NADPH oxidase, which is a 
multi-protein enzyme complex (Figure 3). The NADPH oxidase is known to 
catalyse the generation of the superoxide anion (O2−).  
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The significance of the NADPH oxidase to host defence is distinctly indicated by 
chronic granulomatous disease (CGD), a rare genetic disorder (15). This disease is 
characterized by different genetic abnormalities in important components of the 
NADPH oxidase and as a result it presents as an inactive oxidase. The patients 
suffering from this disease are known to be at risk of severe and recurrent 
infections caused by microorganisms. They are also at risk of developing 
granulomas made by monocyte and macrophage fusions, which have phagocytosed 
microorganisms but do not have the ability to destroy them (15).  
The NADPH oxidase enzyme complex is made of four oxidase-specific proteins 
(p22phox, p47phox, p67phox, and gp91phox) and a rho guanosine triphosphatase 
(GTPase) (Rac1 or 2) (19). When the neutrophils are at rest, components of the 
NADPH oxidase, namely, p67phox, p47phox, and the GTPase Rac2 stay in the 
cytosol and flavocytochrome b558, which is made up of p22phox and gp91phox 
either remain in the plasma membrane or membranes of specific secretary vesicles 
and gelatinase granules(19). Neutrophil priming is an important event in which 
the responsiveness of the neutrophil to a stimulus is rapidly augmented by an 
exposure to priming agents (20). Neutrophil priming agents such as LPS (19), IL-8, 
and TNFα (21), are known to cause a small increase in p47phox phosphorylation. 
For example, when a neutrophil is primed with TNFα LPS it results in the assembly 
of NADPH oxidase. The oxidase is then able to pump electrons from the cytosol 
into the phagosome where it reacts with the intraphagosomal molecular oxygen to 
form superoxide anions. The superoxide anions then undergo spontaneous 
dismutation to form hydrogen peroxide. TNF-α is known to induce a very weak 
oxidative reaction by neutrophils; however, the response is strongly enhanced 
which causes rapid generation of ROS on exposure to a second stimulus, such 
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bacterial fMLP peptide (22). The hydrogen peroxide itself can be bactericidal, 
however, it can be further converted to hypochlorous acid (Figure 3) (23) by 
myeloperoxidase (MPO). Hypochlorous acid is a potent microbiocidal compound 
(19). MPO is a green haem enzyme which accounts for about 5% of the total 
protein in neutrophils (24). MPO is stored in the azurophilic granules and during 
the ingestion of microbes by neutrophils, MPO is released into the phagosome and 
accounts for approximately 25% of the protein in the phagosome (25). 
 
 
Figure 3. Neutrophil killing of bacteria inside phagosome (26). 
 
1.1.4 Degranulation 
Neutrophils contain many storage granules, distributed throughout the cytoplasm. 
Phagocytosis triggers degranulation, which involves cytoplasmic granules fusing 
with the phagosomal membrane and subsequently emptying their contents into 
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the phagosome (27). There are several types of granules: peroxidase negative 
granules such as specific granules, gelatinase granules and secretory granules, and 
peroxidase positive azurophilic granules. Azurophilic granules contain 
microbicidal enzymes like MPO (28). Granules contain many important enzymes, 
contributing to the successful killing of the microbe inside the phagosome (Figure 
3). 
1.1.5 Non-oxidative killing by neutrophils 
Another fundamental mechanism used by neutrophils to kill microbes is a non-
oxidative mechanism. During degranulation, neutrophils deploy many proteins 
and microbicidal peptides, either through extracellular transport into 
inflammatory fluids, or intracellularly into the phagosome. This leads to the 
destruction of the microorganism as a result of exposing it to high concentrations 
of these molecules (29). One of these proteins in particular, 
bactericidal/permeability-increasing protein (BPI), is found in azurophil granules 
on the surface of the neutrophil (29). BPI is known to exhibit several antibacterial 
activities, mainly against gram-negative bacteria. One way it acts to destroy 
microbes is by causing sequential damage to the lipid membranes and bacterial 
outer membrane (30). Secondly, it acts to neutralize bacterial LPS, and lastly, it can 
enhance neutrophil phagocytosis of bacteria by opsonizing the bacteria (29).  
1.1.6 NETs 
Until recently, it was generally believed that neutrophils had two main strategies 
used to destroy microoragnisms, by phagocytosing them and killing them 
intracellularly, and by degranulation releasing antimicrobial proteins into the 
surrounding environment. However, a third strategy has been discovered and 
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known as the formation of neutrophil extracellular traps (NETs) (31). NETs 
emerge from an activated neutrophil when it releases its nuclear DNA (32) and 
mitchondreal DNA (33) into the extracellular space. NETs are structures made up 
of chromatin and granule proteins that capture and kill invading microbes 
extracellularly (32). Fuchs et al. has demonstrated that when neutrophils are 
activated, they initiate a cell death program where their granular and nuclear 
membranes decompose and the decondensed nuclear DNA is released into the 
cytoplasm. Eventually, the plasma membrane breaks and the granular proteins as 
well as the chromatin are extruded into the extracellular space. NET formation can 
occur as a result of direct stimulation by pathogens and the process takes 
approximately 2-3 hours (31). However, another study performed by Clark et al. 
demonstrated that when neutrophils are activated through receptor mediation, it 
generates NETs within minutes. This particular process requires the cells to be 
under flow conditions and has been shown in complications such as sepsis. As 
sepsis is a blood born infection, this mechanism of NET formation could lead to 
capture and destruction of the invading microbe (34).  
1.2 Sepsis 
Sepsis was traditionally described as “blood poisoning” and is now referred to as 
systemic inflammation of the host response towards an infection (35) . It is also 
described as a complicated clinical disorder that is generated from a dangerous or 
detrimental host response to an infection. Sepsis initiates when a normal host 
response towards an infection amplifies and then becomes dysregulated (35). In 
the past, it was thought that sepsis simply depicted anoverstate of the hyper-
inflammatory response where an inflammation-induced organ injury would result 
in patients dying. However, recent data demonstrate that significant heterogeneity 
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is found in septic patients’ inflammatory response, where in some patients it is 
caused by a pro-inflammatory response and in others, the immune response is 
suppressed (36). Being the greatest example of acute infection, sepsis is known to 
cause multi-organ failure and leads to death in about 30-50% of patients and 
remains one of the main causes of death from an infection (37). Statistics indicate 
that the incidence of sepsis has increased between 7- 8% over the last decade in 
the United States of America (USA) and the incidence rate was about 377/100 000 
persons in 2008 (38). In 2007, over 200 000 people died of sepsis complications in 
the USA (39) and sepsis was listed number one as the most expensive 
complications in 2011, costing the USA healthcare system an annual rate of $22.2 
billion (38). Sepsis can be classified into three stages, sepsis, severe sepsis and 
septic shock. Sepsis, which is the first stage of the disease, is defined as a systemic 
inflammatory response to an infection and the symptoms include high or low body 
temperature, elevated heart rate, altered mental status and elevated plasma C 
reactive protein. Severe sepsis is described as sepsis being further complicated by 
organ dysfunction, and septic shock is described as sepsis followed by 
complications such as hypertension despite adequate fluid retention (38).  
1.2.1 Causes of sepsis 
Originally it was believed that gram-negative bacteria were the main organisms 
that triggered bacterial sepsis (40), but over the past two decades, gram-positive 
bacteria have been indicated to be the most prevalent causes of sepsis (41). Some 
of the most leading gram-positive bacteria causing sepsis include Staphylococcus 
aureus and Streptococcus pyogenes and gram-negative bacteria include, Escherichia 
coli , Klebsiella spp and Pseudomonas aeruginosa (42). When pathogens cause 
disease, they usually use a range of virulence factors to protect themselves from 
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the host innate immune response and to facilitate them to successfully cross the 
mucosal barriers (43), spread and to replicate in distant organs (44). Many 
virulence factors are toxins. These toxins include lipopolysachharide (LPS) or 
endotoxin, that exists on the outer membrane of gram-negative bacteria (41). An 
example of a potent toxin produced by S. aureus is toxic shock syndrome toxin-1 
(TSST-1) that is involved in septic shock (35). Another pyrogenic exotoxin that is 
also involved in septic shock is produced by S. pyogenes. Toxic shock syndrome is 
one of the most acute and severe types of septic shock and mortality rates are 
known to be as high as 50% (35). TSST-1 and the exotoxin of S. pyogenes are 
superantigens. Unlike traditional antigens, which normally activate <0.01% of T 
cells, superantigens are able to activate >20% (45) of T cells through directly 
binding to MHC-II and T-cell receptor (46). As a result, there is an enormous 
release of proinflammatory cytokines, consisting of tumour necrosis factor (TNF), 
interleukin-2 (IL-2) and interferon γ (IFN γ), which then leads to toxic shock (47). 
With gram-negative bacteria, such as E. coli, endotoxin is the main cause of lethal 
toxic shock. LPS macromolecules make up approximately 75% of the outer 
membrane of gram-negative bacteria (48) and the hydrophobic lipid A domain is 
the core structure of LPS (49). Lipid A is recognized by TLR4. Ligation of lipid A to 
TLR4 induces production of proinflammatory cytokines such as IL-8, IL-6, IL-1β, 
IL-1, IL-12, and TNFα (50).TNFα is reported to (51) play a crucial role during 
sepsis as it plays a role in inducing further proinflammatory cytokines which then 
leads to more serious complications such as tissue injury (51). TNFα initiates the 
induction of nitric oxide synthase (iNOS) and cycloocygenase (COX-2) which 
catalyzes nitric oxide (NO) and prostaglandin E2 (PGE2) production, respectively 
(52) (53). Both NO and PGE2 have been implicated in sepsis as they are 
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vasodilators that have been indicated to cause a reduction in neutrophil migration 
during neutrophil recruitment by endothelium-leukocyte binding inhibition (53). 
1.2.2 Hyper-inflammation  
As mentioned, bacterial infection can induce systemic inflammation, which leads to 
induction of many pro-inflammatory cytokines predominantly IL-1β, IL-2 IL-6, IL-
8, macrophage migratory inhibitory factor (MIF), NO, PGE2 (54) and most 
importantly TNFα (55). It has been shown that TNFα significantly increased in 
septic patients plasma and in animal models (56) and high serum concentrations 
of these molecules are known to be associated with higher risk of mortality (57). 
However, treatments aimed at antagonizing the activity of these cytokines have 
not improved the patients survival (54). The intensity of the over production of 
these cytokines leads to systemic hyper-inflammation which subsequently results 
in capillary and interstitial damage as well as deposition of fibrin and eventually 
organ damage (58). 
1.2.3 Hypo-inflammation  
After the induction of systemic inflammation initiated by neutrophils, the 
transition neatly changes to a hypo-inflammatory state followed by the occurrence 
of a restorative phase (59). Anti-inflammatory cytokines are some of the key 
players in hypo-inflammation. These cytokines are a group of molecules involved 
in regulating and preventing the harmful effects caused by excessive inflammatory 
reactions. Important anti-inflammatory cytokines involved are IL-1 receptor 
antagonist (IL-1Ra), IL-4, IL-6, IL-11, IL-13 and most importantly IL-10 (60). IL-10 
is the central cytokine involved in the anti-inflammatory response. Regulatory T 
cells (Tregs) (61), CD4+ Th2 cells, B-cells and monocytes produce IL-10 and it is 
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known for powerfully inhibiting the expression of Th-1 cytokines such as IL-2 and 
IFN-γ. It has also been indicated that it suppresses many pro-inflammatory 
cytokines including TNF-α, IL-1, IL-6, IL-8 and IL-12 (60). These anti-inflammatory 
cytokines are found to play a role in sepsis as well. For example, high levels of TNF-
α initiate IL-10 production which in turn is responsible for down regulating the 
immune response through initiation of further anti-inflammatory cytokines (55). 
High abundance of anti-inflammatory cytokines causes immunosuppression in 
sepsis patients characterized by T-cell hypo-responsiveness, which is observed as 
a counter-balancing and sometimes over-response towards the initial pro-
inflammatory situation caused by the immune response (35). This causes an 
insufficient host defence against the pathogen and therefore could be thought of as 
a possible ‘mediator’ of sepsis and eventually leading to progressive organ failure 
(35). 
1.2.4 Abnormalities of neutrophil recruitment to the site of infection during 
sepsis 
Neutrophils play a pivotal role in the innate immune response against pathogens 
in the human body. In the case of sepsis, a series of changes occurs in neutrophil 
functions where they reprogram themselves, their recruitment to infectious sites 
are impaired, they accumulate unusually to unwanted sites and their effector 
responses are unregulated (62). Because recruitment of neutrophils to the site of 
infection is a fundamental part played in the immune response, it is apparent that 
impairment in their recruitment during an infection can cause failure in clearance 
of bacteria during the process of an infection. Under the normal state, a 
polymicrobial infection induces TLR 2 and 4 activation in resident cells and as a 
result, cytokines such as G-CSF/GM-CSF are produced leading to the release of 
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neutrophils from the bone marrow. Increased proinflammatory cytokine and 
chemokine production at the site of infection leads to the release of a high amount 
of circulatory neutrophils that enter the site of infection. The release of these 
proinflammatory molecules initiates a chemoattractant gradient in the 
extracellular matrix and induces chemotactic receptors so that neutrophils 
successfully can make firm attachment before transmigrating to the site of 
infection. Gram-positive bacteria activate TLR2 and gram-negative bacteria 
activate TLR4 on neutrophils leading to phagocytosis of microbes by the 
neutrophils. Surface integrins and CD64 (Fc receptor for IgG) are upregulated to 
promote endothelial adhesion. However, some molecules, such as TNFα and IL8, 
also promote down regulation of chemotactic receptors, such as the L-selectins. As 
a result, neutrophils may bind to endothelium but are less sensitive to the 
underlying chemotactic factors and this leads to failure in neutrophil migration 





Figure 4. Recruitment of neutrophils in healthy individuals (A) and (B) in sepsis patients. 
Red =gram-positive bacteria. Green=gram-negative bacteria. This figure is explained in more detail 
in the main text. Figure taken from (54). 
 
1.3 S. aureus  
Staphylococcus aureus is known as a major pathogen that affects humans and 
causes a broad range of infections (63). The bacterium asymptomatically colonize 
more than 30% of the human population; however, it is capable of causing mild 
infections, such small skin infections, to more severe infections like sepsis (64). 
Individuals who are colonized are at much higher risk of acquiring severe 
nosocomial infections and sepsis caused by S. aureus (65). Bloodstream infections 
caused by S. aureus remain one of the most frequent and hard to treat (66). The 
incidence of bacteraemia, especially caused by methicillin-resistant S. aureus 
(MRSA) (64), has strikingly increased in the United states (67). Bloodstream 
infections caused by S. aureus are recorded to have a high mortality rate of nearly 
30%, which makes it one of the most significant infections worldwide (68). 
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Because there is lack of staphylococcal vaccine, (69), and advancement of the 
development of methicillin resistant S. aureus strains, vancomycin is the only 
remaining choice of antibiotic (70), (71). 
As mentioned previously, neutrophils are the first line of defence against invading 
microorganisms in the human body and kill most invading bacteria, but pathogens 
like S. aureus can avoid being killed by immune cells to survive and subsequently 
cause infections (72). S. aureus is known to carry a significant virulence factor 
known as carotenoid pigment staphyloxanthin which behaves as a detoxifier of 
oxidants produced by neutrophils (73). It is also well known that these bacteria 
can survive inside immune cells in vitro (74). However, recently Surewaard and 
colleagues conducted a study and found that MRSA survive and subsequently 
proliferate inside Kupffer cells (KCs) in the liver. They looked at this by using 
spinning-disk intravital microscopy which allowed them to see the movement of 
MRSA in “real time” in the blood system. Upon injection of mice with MRSA, they 
noticed that KCs were the immune cells responsible for the rapid uptake and 
killing of these bacteria. They observed that a small proportion survived within the 
KCs so they added vancomycin to see if this might eradicate them but vancomycin 
was not able to penetrate the KCs which allowed the bacteria to survive inside the 
cell. When the cells lysed, the bacteria were seen to disseminate into different 
organs in the body including the kidneys (74). This study also found that there 
were differences between KCs and between individual phagosomes within the 
same KC in their capacity to produce superoxide and found that some MRSA were 
not oxidized. It was suggested that the lack of ROS production within these 
phagosomes could lead MRSA to find a niche and replicate within the KCs (74).  
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S. aureus also has the ability to prevent successful neutrophil attraction and 
ingestion, and has the ability to escape killing by neutrophils (75). S. aureus can 
successfully inhibit neutrophil recruitment and phagocytosis through toxins such 
as superantigen-like 5 or through chemotaxis inhibitor protein, or FPR-like 1 
inhibitor proteins (75). There are many ways that S. aureus have developed 
escaping mechanism from being phagocytosed by neutrophil. It has been shown 
that the USA300 strain of S. aureus, has the ability to express leukocidin AB on its 
surface and when exposed to neutrophils, it can form pores in the plasma 
membranes of neutrophil which causes pore formation to the neutrophils and 
subsequently causes neutrophil lysis (76). It has also been observed by the same 
group that leukocidin AB help the bacteria avoid being phagocytosed which in turn 
enables them to successfully survive and replicate in the blood stream (76) As a 
result of the enhanced virulence factors of MRSA strains such leukocidin AB, they 
are able to overcome these important neutrophil functions (75).  
1.4 Aims and Objectives of this thesis 
There is convincing evidence that proinflammatory cytokines are elevated in 
sepsis serum. It would, therefore, be of interest to examine neutrophil killing in the 
presence of sepsis serum rich in inflammatory cytokines. Most of the neutrophil 
killing assays are performed in buffer with the minimum amount of serum 
required for opsonisation. Therefore, when incubated with patience serum the 
neutrophils are not exposed to the levels of inflammatory cytokines present in the 
body during infection. As a result, the media containing minimum serum might not 
reflect the true rate of neutrophil killing. I hypothesized that using a serum 
concentration similar to that in blood, neutrophil killing would be enhanced in 
sepsis serum due to priming by the inflammatory cytokines. When activated these 
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neutrophils would be expected to produce higher levels of reactive oxygen species 
and kill bacteria faster.  
 Several studies have also indicated that S. aureus survive within immune cells and 
subsequently proliferate and cause subsequent infection. In sepsis recurrence of 
infection can happen after antibiotic treatment and this is associated with a poorer 
prognosis for the patient.  
Hypochlorous acid remains one of the powerful oxidants which interacts with with 
most of the cellular macromolecules (77). It is a reactive oxidant, used by the 
neutrophils to kill invading microorganisms. I hypothesized that pre-exposure to a 
sub-lethal dose might render the bacteria more resistant to further doses of HOCl. 
 
The following aims were undertaken to test my hypotheses: 
• To compare killing of S. aureus by neutrophils in serum from healthy donors 
to that in serum from patients with sepsis. 
• To compare the killing of isolates of S. aureus taken from sepsis patients 
before and after antibiotic treatment and also to compare these with killing 
of a laboratory strain of S. aureus. . 
• To compare the survival of bacteria that are pre-treated with a sub-lethal 
dose of HOCl then exposed to a range of doses of HOCl to those treated to 




Section 2 – Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
Heparin was purchased from Fiscons Instruments Pty. Ltd., (New South Wales, 
Australia), Ficoll-Hypaque was purchased from GE Healthcare™ (Uppsala, 
Sweden), deoxyribonuclease (DNase 1) was obtained from Roche (Mannheim, 
Germany), Tumour necrosis factor-alpha (TNFa) was purchased from Invitrogen 
Thermofisher/Life Technologies and all other chemicals were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Columbia sheep blood agar plates were 
obtained from Fort Richard Laboratories Ltd, Auckland, NZ. Deionized water was 
obtained from a Milli Q water purification system from Millipore Corporation, 
Massachusetts 01730, USA.  
2.1.2 Bacteria 
Escherichia coli American type culture collection number (ATCC) 25922 and 
Staphylococcus aureus strain 502a (ATCC 27217) were acquired from the New 
Zealand Communicable Disease Centre (Porirua, New Zealand). The six clinical 
isolates of Staphylococcus aureus used in this study were obtained from the 
Canterbury Health Laboratories (Christchurch, NZ). Staphylococcus aureus taken 
before and after treatments were from the same patient. The study was approved 
by the New Zealand Health and Disabilities Ethics Committee. 
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2.1.3 Sepsis serum samples 
The Canterbury District Health Board (Christchurch, NZ) provided the sepsis 
serum samples (refer to Table 2).  The study was approved by the New Zealand 




Table 2. Background information on the serum samples from sepsis patients 
Sample 
# 
Duration of patient sickness and 
duration on antibiotics before 
sample was taken 
Organism responsible 
for causing the 
infection 
Diagnosis and CRP 
level mg/mL 
1 Unwell 3 days when samples taken 
On antibiotics 236 hours before 
sample taken 
 
Group G. streptococcus  Septicaemia  
CRP 201 
2 Unwell for 14 days 




is of spine 
CRP 140 
3 Unwell for 6 days  
On antibiotics for 2 days  
 
Enterococcus faecalis Pyelonephritis  
CRP 224 
4 Unwell for 5 days  
On antibiotics 4 days before 
 
E. coli  Pyelonephritis 
CRP 267 
5 Unwell for 3 days 
On antibiotics for 2 days 
 
Klebsiella pneumoniae Pyelonephritis  
CRP 373 
6 Unwell for 2 days  
On antibiotics for 1 day 
 
Staphylococcus aureus  Septic arthritis  
CRP 235 
7 Unwell for 6 days 
On antibiotics for 1 day 
 
Enterococcus faecalis  Aortic root abscess  
CRP 250 
8 Unwell for 5 days  
On antibiotics for 4 days  
 
Haemophilus influenzae Pneumonia  
CRP 203 
9 Unwell for 10 days 
On antibiotics for 5 days 




10 Unwell for 4 days 
On antibiotics for 1 day 
 
S. aureus Gastroenteritis  
CRP 111 
11 Unwell 2 days 
On antibiotics for 2 days 
 
S. aureus  Cellulitis 
CRP 134 
12 Unwell for 24 hours 
On antibiotics for < 24 hours 
 
Group G. streptococcus Cellulitis 






Solutions and reagents used in this thesis were shown in Table 3 below. 
Table 3. List of the reagents and buffers used throughout this thesis. 
Substance Preparation 
Phosphate-buffered saline 
(PBS) (10x stock) 
2 g KH2PO4 (15 mM), 11.4 g Na2HPO4 (80 mM) and 2.4 g KCl (27 
mM) in 900 mL of water. The pH was adjusted to pH 7.4 with HCl, 
then 80 g NaCl (1.37 M) was added and the final volume was 
brought to 1 L. Stored at room temperature. 
PBS (1x) 1 part 10× PBS, 9 parts water. Autoclaved before use. 
Hank’s balanced salt 
solution (HBSS) 
1 mM CaCl2, 0.5 mM MgCl2, 1 mg/mL glucose in PBS. Filter-
sterilized before used and stored at 40C. 
Dextran Was made up to 5% (w/v) in normal PBS and was stored at 4
0C. 
Superoxide dismutase 
from bovine liver 
Stock of 2 mg/mL dissolved in PBS and diluted 10 times for use. 
It was stored at −200C. 
Phorbol myristate acetate 
(PMA) 
PMA was made as a stock solution of 2 g/mL in 
dimethylsulphoxide and stored at −200C. A working solution was 
made by diluting to 10 μg/mL in PBS immediately before adding 
to cells. 10 μl was added to 1 mL of cells to give a final 




fMLP was stored as a stock solution of 10 mM in 50% ethanol at 
−200C. A working solution of 100 ng/mL final concentration was 
made by diluting in PBS and stored at −200C.  
DNase 1 mixture Tris–HCl pH 7.4 (250 mM), CaCl2 (25 mM), MgCl2 (12.5 mM), and 
DNase (2,500 U/mL).. 
Hypochlorous acid 
(Janola Premium bleach) 
A stock solution of approximately 6 mM was made fresh each day 
by diluting Janola (10 μl into 990 μl Milli Q water). The stock was 
diluted in HBSS to the required concentration. 
pH 11 water Water was brought to pH 11.0 by adding NaOH immediately 
before use. 
Tumour Necrosis Factor 
alpha 
Stock of 100 ng/mL stored at -20 0C was diluted in media to a 
working solution of 20 ng/Ml. 
 
Cytochrome c (from 
equine heart) 
Was made up to 5% (w/v) in normal PBS and was stored at 40C. 
 
 
2.2.1 Preparation of bacteria 
Staphylococcus aureus lab strain, clinical isolates of Staphylococcus aureus and E. 
coli were stored at −80°C in 3% (w/v) tryptone soy broth and 15% glycerol. 
 
24 
Periodically, a loop of bacteria was transferred from the frozen stock onto a 
Columbia sheep blood agar plate, incubated overnight at 37°C then stored at 4°C. 
The Agar plate was routinely sub-cultured every fortnight to maintain a working 
stock of bacteria. When needed, 10 ml of tryptone soy broth (3% w/v) was 
inoculated with a single colony from the plate and was grown at 37°C on a shaker 
(200 rpm) overnight until they reached a stationary phase of growth. The bacteria 
were pelleted by centrifugation at 12,000 x g for 4 minutes followed by washing 
twice in PBS. After the final wash, the bacteria were suspended in HBSS and 
centrifuged at 150 x g for 5 minutes to remove any clumped cells. Collecting the 
supernatant, the bacterial concentration was determined by measuring A550 and 
relating this to a standard curve of turbidity against colony-forming units 
previously established by others in the lab. An absorbance (A550) of 0.178 gave 
approximately 1 × 108 /ml S. aureus  and 0.196 gave approximately 1 × 108 /ml  E. 
coli) which were previously established by others in the lab.  
2.2.2 Preparation of serum  
Autologous whole blood (5 ml) was collected from either healthy controls or sepsis 
patients with informed consent, in a vacutainer tube without anticoagulant and left 
to clot at 37°C for one hour before the serum was separated by centrifugation at 
1200 x g for 2 minutes at room temperature. Contaminating red blood cells were 
removed by centrifugation at 12,000 x g for 1 minute then serum was either used 
immediately or stored in aliquots at −20°C for maximum of six months before use. 
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2.2.3 Opsonisation of bacteria 
Bacteria (1 × 108 /ml) were opsonized in HBSS containing either 50% healthy 
serum or 50% sepsis patient serum in glass tubes at 37°C for 20 minutes with 
gentle rotation at 6 rpm.  
2.2.4 Isolation of neutrophils 
Neutrophils were isolated from healthy human volunteers after obtaining their 
fully informed consent. The Southern Health and Disability Ethics Committee 
approved this study (URA/10/03/021). Neutrophil isolation was carried out under 
sterile conditions at room temperature and cells were used within 1–2 hours of 
preparation. Whole blood (50 ml) was collected from donors by venipuncture into 
a sterile tube containing 100 μl of 5000-units/ml heparin. Neutrophils were 
isolated by dextran sedimentation followed by Ficoll-Hypaque separation as per 
modified protocol based on a method by Boyum (78). The heparinized blood was 
diluted 1:3 with PBS before the addition of 5% dextran to give a final 
concentration of 1% dextran. After gently mixing the contents of the tube, red 
blood cells were sedimented by incubation at room temperature for 20–25 
minutes then the leukocyte-enriched upper layer was removed and gently 
dispensed into 15 ml Falcon tubes, up to 11 ml per tube. Each tube was then 
underlaid with 3 ml Ficoll-Hypaque before being centrifuged (Eppindorf 
Centrifuge 5810) in a swing out rotator at 1000 x g for 20 minutes at room 
temperature with no brake. The supernatants containing plasma and peripheral 
blood mononuclear cells (PBMC) were carefully removed ensuring the PBMCs did 
not contaminate the pellet. The remaining red blood cells and granulocytes were 
first suspended in 500 μl PBS and then transferred to 50 ml Falcon tubes and the 
volume was made up to 10 ml with PBS solution. The red blood cells were lysed by 
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adding 20 ml of distilled water. After 2 minutes, 10 ml of 2.7% (w/v) NaCl was 
immediately added to the suspension to restore isotonicity. The volume was made 
up to a total of 50 ml by adding 10 ml PBS and it was centrifuged at 450 x g for 5 
minutes at room temperature. The neutrophil pellet was suspended in 5 ml HBSS, 
typically resulting in 1.1–3.5 x 106 neutrophils/ml of blood. Cells were stained with 
trypan blue and counted using a haemocytometer to determine neutrophil viability 
and yield, and purity was assessed by FSC versus SCC following gating to exclude 
debris. No antibody labelling was used by flow cytometry. This preparation method 
resulted in an approximately 95–98% pure population of granulocytes. 
2.2.5 Killing assay 
The neutrophil killing assay was conducted as described in (79). Both one-step and 
two-step (Figure 5) killing methods are described below. The one-step protocol 
requires less manual processing of samples and it is used to determine if a 
bacterium is killed by neutrophils. It allows for the measurement of a composite 
rate of neutrophil phagocytosis. However, the two-step killing assay (Figure 5) 
measures phagocytosis and killing independently. It requires an extra 
centrifugation step (differential centrifugation), where the intracellular bacteria 
(ingested) are separated from the extracellular bacteria. The amount of viable 
intracellular and extracellular bacteria is then measured at different times 
followed by a kinetic analysis, enabling separate rate constants to be worked out 




 Figure 5. Outline of the two-step killing method. Figure adapted from (79). 
 
 
Neutrophils at a volume of 300 μl (1 × 107 cells/ml) were pre warmed in 1.5 ml 
Eppendorf tubes at 37°C for 30 minutes in HBSS containing 50% serum from 
either healthy donors or sepsis patients (experimental tubes). To account for the 
growth of bacteria over the time-course of the experiment, control tubes of 
bacteria alone were also prepared by replacing the neutrophils with HBSS. 
Inhibitors were added to the appropriate tubes 5 minutes before the addition of 
bacteria. Freshly opsonized 300 μl bacteria (300 μl at 1 × 108/ml) were added to 
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the neutrophils (ratio of bacteria to neutrophils 10:1) then incubated with rotation 
(6 rpm) at 37°C. For the time course assay, 50 μl samples were collected from the 
experimental tubes at the required times and the reaction was stopped by placing 
the samples on melting ice immediately. For the two-step killing protocol, at this 
step the samples were diluted in 950 µL of ice cold PBS to halt neutrophil activity 
and were placed on melting ice. Samples were then centrifuged at 100 x g for 5min 
at 4°C using a swing out rotor. The supernatants, being careful not to disturb the 
neutrophil pellet, were collected and pellets were washed twice with 950 µL ice 
cold PBS (100 x g, 5min, 4°C) pooling the supernatants. The pooled supernatants 
contained the extracellular bacteria while the phagocytosed bacteria were in the 
neutrophil pellet. Samples from the control tubes of bacteria alone were collected 
at time zero and the last time point. To release the intracellular bacteria, both for 
the one-step and two-step killing assays the neutrophils were lysed by diluting the 
samples into 910 µL pH11 dH2O for 5 minutes at room temperature and the 
control samples were treated the same. Samples were then vortexed vigorously for 
5s to disperse the bacteria before the addition of 40 µl DNase mixture at a final 
concentration of 100 U DNase. The purpose of adding DNase was to degrade the 
DNA released from the neutrophils during the lysis step and, therefore, prevent the 
bacteria from sticking to the DNA strands. In the control tubes, DNase mixture was 
replaced with 40 μL pH11 dH2O as there were no DNA strands released in these 
samples. Control experiments had shown that the pH11 dH2O had no effect on S. 
aureus viability. After lysis samples were then incubated at 37°C for 10 min to 
allow for DNA degradation. Controls were incubated under the same conditions. 
Samples were then diluted in ice cold pH 11 dH2O to provide a concentration of 
approximately 5000 CFU per mL (refer to Table 3 for dilutions) and then 20 μL 
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aliquots were plated per half a Columbia sheep blood agar plate providing 
approximately 100 CFU per half plate. Dilution factors for the 2-step assay were 
calculated in a similar fashion (Table 4) but with allowance for the extra dilution of 
the extracellular bacteria during processing. For each sample at least four half 
plates were plated and were then incubated overnight at 37C.  
 
2.2.5.1 Calculations for the one-step killing assay 
The next day the resulting colonies were counted and the colony counts were 
converted back to bacterial concentrations by multiplying by the appropriate 
dilution factor (refer to Table 4 below). The growth of bacteria was accounted for 
over the time course of the assay by plotting the number of ‘control’ bacteria at the 
beginning and end of the experiment. These calculations were based on the 
assumption that the bacteria grow at the same rate in the presence of neutrophils. 
Raw values of viable bacteria against time were plotted using Microsoft Excel 2013 
(© Microsoft Corporation 2013) or converted to percentage survival compared to 
the number of bacteria at the relative time point. Separate experiments were 
compared by fitting an exponential curve to the data (y=y0e−kx). This provided a 
single rate constant, k, which was a combined measurement of phagocytosis and 





Table 4. Suggested dilutions for the one-step protocol a. 
Sample time 
 0 min 10 min 20 min 30 min 40 min 
Approx. undiluted 
concentration/mL a 
5 x 107 4 x 107 3 x 107 2 x 107 2 x 107 
Dilution due to sample 
processing 
1 in 20 1 in 20 1 in 20 1 in 20 1 in 20 
Dilution incurred by plating 20 
μL 
1 in 50 1 in 50 1 in 50 1 in 50 1 in 50 
Further dilution to give approx. 
100 colonies per 20 μL 
1000 700 400 200 200 
Total dilution factor 1 x 106 7 x 105 4 x 105 2 x 105 2 x 105 
a From the observations made previously in our lab, these are the approximate bacterial 
concentrations expected at time of sampling. These values are likely to vary under different 
conditions. If the numbers of bacteria detected are too high (>200) or low (<20) to make accurate 
colony counts, the additional dilutions should be adjusted accordingly. 
This table is adapted from (79) with appropriate minor changes incorporated. 
 
2.2.5.2 Calculations for the two-step killing assay 
Calculation for the two-step assay is based on the Excel spreadsheet written by 
Parker et al. (79). Briefly, the killing rate was quantified by using a kinetic analysis. 
Phagocytosis and killing were determined to follow a first order process (see 
below), therefore, rate constants for both could be measured (80), rate constants 
for both phagocytosis and killing can be measured. A decrease in the number of 
extracellular (A) and an increase in the number of intracellular (B) was observed 
initially, but then a decrease in intracellular was observed as the bacteria were 
killed (C). This was true for all the strains of S. aureus used in this thesis when 
checked with the two-step method. The following equations were adapted from 






Values were derived for A and B at different points in time, and rate constants for 
phagocytosis (kp) and killing (kk) were calculated. Equation 1 represents 
phagocytosis and equation 2 represents killing. These two equations can be 
integrated to derive equations 3 and 4. The initial number of bacteria = A0, and t = 
time. 
 
Calculation of rate constants for both phagocytosis and killing were required to 
follow first order kinetics and kp was measured using equation 3 by obtaining the 
slope of a semi-log plot of A with time. First order kinetics were confirmed with a 
linear fit. Calculations for kk were made by rearranging equation 4 as per the 
protocol given in the supplementary material in Parker et al. (79). The values of kk 
for each time point were then averaged to give the mean value kk. Using the 




2.2.6 Neutrophil stimulation and measurement of superoxide production 
The amount of superoxide produced by neutrophils was measured by its ability to 
reduce cytochrome c, which was monitored as the change in absorbance at 550 nm 
(81). Neutrophils at a concentration of 1 x 106/mL were incubated at 37°C with 40 
μM cytochrome c and 20 μg/ml catalase with or without the priming agent TNFα 
for 10 minutes at a final concentraion of 20 ng/ml. A control tube included 20 
μg/mL of superoxide dismutase to confirm that any changes in absorbance were 
due to superoxide production. The stimulus, either fMLP at 100 ng/mL or PMA at 
100 ng/mL, was added and the absorbance was measured at 550 nm for 5 minutes 
using an Hitachi spectrophotometer (UV solutions Application program no. 
2J24311-04). This control allowed measurement of cytochrome c reduction not 
due to superoxide.  
2.2.7 Phagocytosis assay 
Neutrophils pre-incubated in either 50% healthy or sepsis serum for 30 minutes 
were incubated with opsonized S. aureus in a glass tube for 30 minutes at 37°C 
with gentle rotation (6 rpm). For the time course, 50 μl samples were taken from 
the experimental tube at each time point and for the controls 50 μl samples were 
taken at zero and last time point. Reaction was stopped by placing the tube on 
melting ice immediately. Samples were then diluted in 950 μl ice cold PBS and cells 
were pelleted at 100 x g for 5 minutes at 4°C and supernatents were collected. 
Cells were then washed 2 times with 1 ml ice cold PBS and supernatents were 
collected and pooled while keeping them on ice. Supernatants were then diluted in 
ice cold pH 11 water, plated and incubated overnight at 37°C. Colony counts were 
converted back to bacterial concentration by multiplying by the appropriate 
dilution factors and the growth of bacteria were taken into account over the time 
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course of the assay. Calculations for phagocytosis were determined in the same 
way explained in section (2.2.5.2). Phagocytosis rates were determined and an 
approximate linear fit to a semi-log graph confirmed that phagocytosis followed 
first order kinetics. 
2.2.8 HOCl killing of S. aureus 
This experiment was conducted to see if our lab strain of S. aureus became more 
resistant to killing when it was treated a second time with HOCl after exposure to a 
sub-lethal dose of HOCl.  
2.2.8.1 HOCl preparation 
HOCl was prepared as per Table 3 and the absorbance was measured at 292 nm. 
The spectrophotometer was blanked with 800 μl of 200 mM KOH in a quartz 
cuvette and the concentration of HOCl was measured by adding 200 μl of stock 
HOCl to the cuvette. The concentration of the HOCl in the stock was measured by 
using the following equation: 
 
A = εcl 
where: 
A = absorbance at 292 nm 
ε = extinction coefficient 350 M−1 cm−1 
c = concentration mol l-1 
l = path length (1 cm) 
 
Thus, 




The concentration of HOCl was approximately 6 mM and was diluted further in 
water to make 1 mM. Just before use, the 1mM stock was then diluted in HBBS to 
the required amount, 35, 50, 75, 100 nMoles. Bacteria were prepared as in section 
2.2.1 Preparation of bacteria. A sub lethal dose of 35 nMoles HOCl/10 9 S. aureus 
was established by deriving a standard curve.  
2.2.8.2 HOCl killing assay 
For every concentration of HOCl tested, there were two tubes prepared with the 
same amount of bacteria. Bacteria were either given HBSS or they were exposed to 
35 nMoles of HOCl (Fig. 6). Tubes were then incubated with rotation (6 rpm) at 
37°C for 30 minutes. After this time, the bacteria were treated with varying 
concentrations of HOCl and were incubated for a further 15 minutes with rotation 
(6 rpm) at 37°C. Finally, 1mM methionine was added to scavenge any remaining 
HOCl in order to stop the reaction. Control tubes were prepared with bacteria 
alone (109 cells) and HOCl was replaced with HBSS. Samples (50 μL) were taken at 
time zero (before addition of 35 nMoles HOCl) and at the end of the experiment. 
Samples were then diluted in ice cold pH 11 dH2O to approximately 5000 CFU/mL 
and then 20 μL aliquots were plated per half a Columbia sheep blood agar plate, 
providing approximately 100 CFU per half plate. For each sample at least four half 
plates were plated and were then incubated overnight at 37C. The next day 
colonies were counted and the colony counts were converted back to bacterial 
concentrations by multiplying by the appropriate dilution. Raw values of viable 
bacteria against HOCl amount were plotted using Microsoft Excel 2013 (© 





Figure 6. Measurement of HOCl killing of S. aureus. 
S. aureus at 109/ml were incubated either in HBSS alone (A), or in the presence of 35 nMoles HOCl 
(B), for 30 minutes. Both A and B then were exposed to varying amounts of HOCl (35–100 nMoles 
HOCl) for a further 15 minutes. 
 
2.2.10 Statistical analysis  
Results are the mean ± SD. Data were analysed either by t test or paired t test. A 




Section 3 – Results 
3.1 Adaptation of one–step neutrophil killing method 
The one-step method used in our lab for neutrophil killing of bacteria was used to 
assay neutrophil killing of our lab stain of S. aureus. The bacteria were opsonised in 
10% autologous serum (serum from the same donor as the neutrophils) before 
adding to pre-warmed neutrophil. The ratio of bacteria of neutrophils was 10:1. 
They then incubated at 37O C with a rotation of 6 rpm and samples were taken at 0, 
1, 10, 20, and 30 minutes.  
The bacteria were opsonized before adding to the neutrophils, and the 
concentration of serum was maintained constant throughout the assay to ensure 
that phagocytosis was occurring at maximum rate once neutrophils were added. 
During the assay, it would be expected that the number of bacteria would increase 
in the absence of neutrophils. In order to account for the growth of bacteria, a 
control tube containing bacteria in the appropriate experimental buffer without 
neutrophils was incubated. Samples were taken at time 0 and at the end of the 
assay and bacterial numbers were determined for each time points. The numbers 
of viable bacteria in the experimental tube were corrected taking into account the 
growth that occurred. This is based on the assumption that even when neutrophils 
are present, viable bacteria would divide at the same rate (80).  
Samples were then diluted and plated and bacterial viability was determined by 
colony counting. An exponential decay was fitted and the result showed (Figure 
7A) that there was good exponential loss of bacteria over time and meant that the 
assay was working as expected. Using the method described in section 2.2.5.1 
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Calculations for the one-step killing assay, the rate constant for phagocytosis and 
killing (k) was calculated to be 0.037 min−1 and t1/2 = 20 min.  
Previously, it has been shown in the lab that killing of S. aureus is predominantly 
dependent on oxidation and inhibition of NADPH oxidase and that MPO decreased 
killing (82). The effects of diphenylene iodonium (DPI), a NADPH oxidase inhibitor 
and 2-thioxanthines (TX1) a myeloperoxidase inhibitor was also tested to see that 
the assay was working under the condition and inhibiting neutrophils from killing 
S. aureus. Figure 7B shows that DPI was very effective as 94% bacteria were viable 
in the presence of 10 μM DPI compared to 30% without inhibitor (p value = 
0.0001) while 56% bacteria viable in the presence of 10 μM TX1, which similar to 
results previously shown in the lab (83). There was no significant difference 
between the number of viable S. aureus with 10 μM DPI compared to S. aureus 




Figure 7. Measurement of the bacteriocidal activity of neutrophils by one-step colony 
forming unit (CFU) assay. 
S. aureus were opsonised for 20 minutes with 10% autologous serum before addition to 
neutrophils (A) (10:1 ratio of bacteria to neutrophils) or (B) neutrophils pre-treated with either 10 
μM DPI (NADPH inhibitor) or TX1 (Myeloperoxidase inhibitor) for 10 min and incubation at 37°C 
with gentle rotation (6 rpm) for 40 minutes. All samples were processed as described in methods 
section using the one-step protocol. The means ±SD of three separate experiments are shown using 
neutrophils from different donors. Data were fitted to an exponential decay curve for A. Analysis 
for the effect of inhibitors were performed at 30 min and data were expressed as a percentage of 
control (S. a) bacteria alone and were compared to S. aureus incubated with neutrophils without 





3.1.1 The effect of serum concentration on the killing of S. aureus by 
neutrophils 
The goal of this experiment was to determine if neutrophil killing of S. aureus was 
different in 10% healthy serum compared to 50% healthy serum. The reason for 
this was to find out if there were any differences detected, then subsequent 
experiments with sepsis serum would be carried out using the 50% serum 
concentration in order to maximize any effect of inflammatory components in the 
sepsis blood, by having minimal dilution. 
The result in Figure 8A shows that there was no significant difference in the rate of 
loss of viable S. aureus between 10% or 50% healthy serum. Bacterial viability was 
similar between the two conditions at each time point. This meant that I could 
continue the rest of the experiments in 50% serum. The rate constant for 
phagocytosis and killing (k) in 10% serum was calculated to be 0.0246 min−1 and 
t1/2 = 28 min and the rate constant for phagocytosis and killing (k) in 50% was 
0.0261 min−1 and t1/2 = 27 min. The rates appeared to be slower than what was 
seen in Figure 7A, however, it still showed a good exponential loss over time. This 
could be due to variability between neutrophils from different donors. 
Next, I planned to see whether the effect of NADPH oxidase inhibitor DPI, on 
neutrophil killing of S. aureus in 50% serum compared to 10% serum. However, in 
the presence of the normal concentration of 10 μM DPI, S. aureus viability was only 
68% (Figure 8B) which was significantly less than that observed in Figure 7B (p 
value = 0.006). Therefore, I tried a higher concentration of DPI, 50 μM to see if the 
S. aureus viability was any better and the result showed only 70% viability in the 
presence of 50 μM DPI which was not significantly different to 10 μM DPI in 50 % 
serum (p value = 0.847). It was thought that the high serum concentration was 
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affecting the inhibitory role of DPI and as a result, I tried a higher concentration of 
100 μM. This showed about 79% S. aureus viability (Figure 8B), which was not 
comparable to that observed by 10 μM DPI in 10% serum with a significant 
difference (P value = 0.049). However, it was similar to what was shown 








Figure 8. Measurement of the bacteriocidal activity of neutrophils and the effect of different 
concentrations of DPI in 10% serum compared to 50% using the one-step killing method. 
S. aureus were opsonised for 20 minutes in either 10% or 50% autologous serum before addition to 
neutrophils (Figure 8A)(10:1 ratio of bacteria to neutrophils) or neutrophils pre-treated with 
varying concentrations of DPI (Figure 8B) for 10 min. S. aureus were incubated with neutrophils at 
37°C with gentle rotation (6 rpm) for 0–30 minutes. Analysis was done as in Figure 7. The mean 







3.2 Neutrophil killing of S. aureus in the presence of healthy and 
sepsis serum 
Sepsis serums were collected from patients (n=12) who were ill from 1–14 days 
and on antibiotics between 1–7 days. Their CRP plasma levels were ranging from 
109 to 373 mg/mL and the majority of infections were caused by gram-positive 
bacteria. Patients were suffering from infections such as cellulitis, aortic root 
abscess, and pyelonephritis.  
In this section I look at neutrophil killing of S. aureus in 50% healthy serum and 
50% sepsis serum to see the effect of the media high in pro-inflammatory 
cytokines present in sepsis serum on the ability of neutrophil killing of S. aureus 
compared to healthy serum. 
3.2.1 Superoxide production of neutrophils pre-treated in healthy normal 
serum and sepsis serum 
For this experiment, I sought to determine whether incubating neutrophils in 
sepsis serum would prime them to subsequently generate more superoxide when 
stimulated with Formyl-methionyl-leucyl-phenylalanine (fMLP) than when 
neutrophils were incubated with healthy serum. This is because we knew from the 
literature that sepsis serum generally contain large amounts of pro-inflammatory 
cytokines such as tumour necrosis factor (TNFα) (85).  
Neutrophils were incubated in either HBSS alone (no serum), 50% healthy or 50% 
sepsis serum, for 30 minutes. The serum was then removed by washing so that it 
would not interfere with the assay. Neutrophils incubated in all three conditions 
were then tested to see if they produced superoxide normally by stimulating them 
with 100 ng/ml final concentration of PMA. The expected amount of superoxide 
shown by others in the lab is approximately 7µM superoxide/min/106 cells. The 
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result (Table 5) indicates that neutrophils in all three conditions produce similar 
amounts of superoxide. Next, I wanted to determine superoxide production by 
stimulating neutrophils with fMLP. Neutrophils were incubated under all three 
conditions and were then stimulated with fMLP (100 ng/mL). Incubation in either 
no serum or 50% healthy normal serum led neutrophils to produce similar rates of 
superoxide as those stimulated with PMA (100 ng/mL).  
PMA was used as a neutrophil stimulant as it is a common soluble stimulator of 
NADPH oxidase and it achieves this by activating protein kinase c which then 
catalyses the assembly of NADPH oxidase components (86). PMA gave extended 
superoxide production over the five minutes while fMLP gave a sharp increase and 
then plateaued within 1–2 minutes. When cells were being pre-treated with TNFα, 
the readings were made for the 20-minute period during the pre-treatment and 
the result showed no superoxide production, confirming that TNFα did not induce 
superoxide production. 
Interestingly, cells incubated in sepsis serum followed by fMLP stimulation 
showed significantly increased superoxide production compared to cells incubated 
in healthy serum (p = 0.031). Neutrophils incubated in no serum and primed with 
TNFα first for 20 minutes followed by fMLP stimulation also showed increased 
superoxide production. However, cells incubated in healthy serum did not show 
increased superoxide production. Also, addition of TNFα had a minor effect on 
superoxide production when cells were incubated in sepsis serum, compared to 
cells incubated in sepsis serum followed by fMLP stimulation with a p value of 
0.5231. The interesting result obtained from this experiment was that neutrophils 
pre-treated in sepsis serum were primed and as a result produced an increased 
amount of superoxide after fMLP stimulation. This led me to my next experiment 
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to find out whether neutrophils kill S. aureus differently in the presence of sepsis 
serum than those in normal healthy serum. 
 
Table 5. Production of superoxide by neutrophils in healthy and sepsis serum (μM 
superoxide produced by /min/106 cells). 
Treatment No serum  Healthy serum  Sepsis serum  
N + PMA 6.5 ± 1.3 5.9 ± 1.2 6.1 ± 0.9 
N + fMLP 6.4± 0.9 6.4 ± 0.6 11.7 ± 1.5 
N + TNFα + fMLP 13.2 ± 0.9 7.2 ± 1.6 13.0 ± 1.1 
Measurement of neutrophil superoxide production using Cytochrome C assay. Neutrophils 
(1x106) were incubated in either no serum or 50% either healthy or sepsis serum for 30 minutes 
followed by a wash in PBS and suspension in HBBS. Neutrophils were then either stimulated with 
PMA alone, fMLP alone or TNFα followed by fMLP. Rates were measured within the first 5 min. The 
means ±SD of three separate experiments are shown using three different donor and sepsis serums. 
Important results are shown in bold. 
 
 
3.2.2. Neutrophil killing in healthy and sepsis serum using the one-step 
protocol  
This experiment was conducted in order to check if neutrophil killing of S. aureus 
was different in healthy serum to that in sepsis patient serum. Bacteria were 
opsonised in 50% sepsis serum or healthy serum for 20 minutes before they were 
added to neutrophils incubated in either 50% sepsis serum or healthy serum for 
30 minutes. The one-step neutrophil killing assay was used to carry out this 
experiment. This assay gives a composite measurement of phagocytosis and 
killing. This particular method was used to see if there were any major differences 
in neutrophil killing between the two conditions. The result indicated (Figure 9A) 
that there were no significant differences in the killing of S. aureus by neutrophils 
in healthy and sepsis serum. The composite rate of phagocytosis and killing (k) 
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was calculated by fitting an exponential curve to the data. The rate of neutrophil 
phagocytosis and killing of S. aureus in healthy serum was 0.0317 mins−1, t1/2 = 22 
mins and in sepsis serum, 0.0281 mins−1, t1/2 = 25 mins with a P value = 0.199. 
Since neutrophil kills S. aureus by oxidative mechanism (87), the effect of an 
inhibitor, diphenylene iodonium (DPI), which is a general inhibitor of flavoproteins 
such as NADPH oxidase, was checked to see if there was any difference between 
the mechanism of neutrophil killing of S. aureus in both serums. The result (Figure 
10) shows there was no significant differences in the number of viable bacteria 
between the healthy and sepsis serum. In both conditions DPI blocked the majority 
of killing to a similar level. The percentage by which DPI inhibited in healthy serum 





Figure 9. Analysis of S. aureus killing by neutrophils in healthy and sepsis serum using a one-
step colony forming unit (CFU) assay. 
Neutrophils were incubated in either 50% healthy or sepsis serum for 30 minutes followed by 
incubation at 37°C. S. aureus were opsonised for 20 minutes with either 50% healthy or 50% sepsis 
serum. S. aureus were added to neutrophils at a ratio of 10:1 (bacteria to neutrophils) and 
incubated at 37°C with gentle rotation for 0 – 40 minutes. A shows viable S. aureus as a percentage 
of control (S. aureus alone) The mean ±SD of seven separate experiments from seven different 
healthy or sepsis serum are shown. B healthy, and C sepsis serum are from a representation of one 
experiment. Viable S. aureus are shown in CFU/ml, taking into account the growth of bacteria 











k (min−1) t½ (min) k (min−1) t½ (min) 
1 0.026 27.3 0.028 25.5 
2 0.029 24.4 0.021 33.2 
3 0.036 19.3 0.023 30.7 
4 0.039 17.8 0.036 19.6 
5 0.032 21.9 0.030 23.3 
6 0.035 20.0 0.036 19.0 
7 0.034 20.0 0.029 23.5 
Experiments were performed as per protocol on Figure 9. Experiments were performed on 
different days with different healthy and individual sepsis serum. On each day the same healthy 




Figure 10. Measurement of neutrophil killing of S. aureus in the presence of diphenylene 
iodonium (DPI) utilizing the one-step killing method. 
Bacteria and neutrophils were prepared as in Figure 9. Pre-treated neutrophils in either healthy 
(blue) or sepsis (red) neutrophils were incubated in the presence of 100 μM DPI (+DPI) for 10 min 
before adding the bacteria. Samples were taken after 30 min incubation with neutrophils. Colony 
counts are expressed as a percentage of control S. aureus alone at time zero (dotted line). S. aureus 
were incubated with neutrophils pre-treated with healthy or sepsis serum without DPI (N+ S. a) 
and sample were taken at 30 minThe means ±sd of 3 separate experiments are plotted using 
separate 3 separate healthy or sepsis serum. 
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3.2.3. The rate of phagocytosis of S. aureus by neutrophils in healthy and 
sepsis serum 
In the previous experiment, I showed that neutrophils in sepsis serum kill S. aureus 
just as well as they kill in normal healthy serum. The one-step assay provides a 
composite measurement of phagocytosis and killing. If uptake of bacteria was 
faster and killing was slow in one medium (e.g., healthy serum), and uptake was 
slow and killing was fast in the other medium (e.g., sepsis), similar results would 
be obtained using the one-step method. Therefore, rates of phagocytosis method 
were determined in the different media. In this method, intracellular bacteria are 
separated from the extracellular by a low speed spin and the decrease in 
extracellular bacteria gives a measure of phagocytosis. Figure 11 shows that there 
was no significant difference in the rates of phagocytosis of S. aureus by 
neutrophils in healthy or sepsis serum. The rate of phagocytosis (kp) in healthy 
serum was kp = 0.0525 min−1, t1/2 = 13 min, and in sepsis serum kp = 0.0465 min−1, 
t1/2 = 15 min with a p value of 0.575 a paired t-test.  
As indicated in Figure 11, there was an initial drop at 3 min time point, which was 
not a good fit for an exponential line. This could be due to lower recovery after 
mixing and spinning the sample. However, there seemed to an exponential loss 
following that, but regardless of the initial drop, there were no significant 




Figure 11. Analysis of phagocytosis of S. aureus by neutrophils using the phagocytosis 
protocol. 
S. aureus were opsonised for 20 minutes with either 50% healthy serum or 50% sepsis serum 
before addition to neutrophils (10:1 ratio bacteria to neutrophils) pre-incubated in either 50% 
healthy or 50% sepsis serum for 30 minutes. This was followed by incubation at 37°C with gentle 
rotation for 0–20 minutes. Samples were collected over time and the supernatants were collected 
for analysis. The mean ±SD of three separate experiments are shown. 
 
3.3 Neutrophil killing of pathogenic S. aureus (clinical isolates) 
compared to the lab strain of S. aureus 
The “before” samples were taken from patients who were admitted to hospital 
with a positive blood culture S. aureus. The “after” samples were taken from the 
same patients who had had a positive blood culture after 2–4 days after treatment 
with antibiotics suggesting poorer prognosis (88). To test whether they were 
already resistant to PNM or became resistant, six pairs of isolates were obtained 
for my experiment from the Canterbury Health Laboratory. They were stored at 
−80oC on sepharose beads and then I grew them on blood agar and used a two-step 
neutrophil killing method to see if there were any differences between the rates of 
killing and phagocytosis between before isolates and after isolates, and to compare 
 
50 
both to the lab strain to see if there were any differences between the rates of 
killing and phagocytosis. For every experiment, one before-sample and one after-
sample, as well as a lab strain, were checked with the same donor neutrophils and 
10% autologous serum. It was hypothesized that the clinical isolates might be 
more resistant to the killing by neutrophils or had developed resistance as they 
had survived the defences of the immune system as well as antibiotic treatments. 
3.3.1. Neutrophil killing of pathogenic S. aureus isolates and lab strain of S. 
aureus using the two-step assay 
The two-step killing was used to check the phagocytosis and killing of before- and 
after- and lab-strain S. aureus. Data were put on a semi-log graph, which gave a 
reasonable linear relationship but not a perfectly linear line (Figure 12A). As 
shown in Figure 12A, the fit for the first 2 points was not linear as there was an 
initial rapid drop which is also evident in Figure 12C. The semi-log plot only gave 
an approximate linear line for all the time point even though the loss was not 
exponential at the start. This was similar for all the experiments done including the 
phagocytosis (Figure 11). The numbers from Figure 12A were used to generate the 
numbers for Figure 12C by using the equations explained in the two-step 
calculations in section 2.2.2.5.2.  In order for the phagocytosis and killing to be a 
first order kinetics, the line should be linear on a semi-log graph. However, as 
results show in my experiments, the lines were not perfect but still an 
approximation.  
As a result, rate constants for phagocytosis and killing and subsequently half-lives 
were measured (Table 7) and all the means for phagocytosis and killing (Table 8) 
were compared. Despite not being a perfect linear relationship, there were no 
significant differences in the rate of phagocytosis between lab strain (kp = 0.065 
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min−1) and before strains (kp = 0.059 min−1); p=0.114 as well no significant 
difference between the killing rate of lab and before strain (kk = 0.15min−1 , kk = 
0.15min−1; p= 0.815) using a paired t-test.. The mean phagocytosis rate of before 
and after samples compared and again no differences were found, p=0.679. The 
result also indicated that there were no significant differences in the rate of killing 




Figure 12. Calculation of rate constants for phagocytosis (kp) and killing (kk) of S. aureus 
using results obtained from the two step protocol. 
Example data for a laboratory strain. Colony counts were converted back to bacterial concentration 
and kp was measured from the slope of the regression line for a semi-log plot of extracellular 
bacteria against time (A) or from the exponential plot (C) for the extracellular counts. Here it shows 
kp = 0.066 min−1 and t1/2 = 10.2 min. Rate constants of killing (kk) (B) was also calculated for each 
time sample was taken. Here the kk = 0.2 min−1 and t 1/2 = 3.5 min. The green line represents the 
expected number of viable intracellular bacteria if no killing occurred, the red line are values for 




Table 7. Rates of phagocytosis and killing of 6 before and after clinical isolates of S.aureus 
and laboratory strain. 
Sample 
Phagocytosis Killing 
kp (min−1) t½ (min) kk (min−1) t½ (min) 
1 
Lab 0.082 8.4 0.19 3.7 
Before  0.065 10.6 0.18 3.9 
After  0.066 10.5 0.18 3.8 
2 
Lab 0.069 10.1 0.09 7.2 
Before  0.067 10.3 0.11 6.3 
After  0.068 10.2 0.11 6.1 
3 
3 Lab 0.063 11 0.12 5.7 
3 Before  0.056 12.4 0.12 5.6 
3 After  0.058 11.9 0.14 4.9 
4 
4 Lab 0.052 13.3 0.19 3.5 
4 Before  0.057 12.1 0.16 4.3 
4 After  0.055 12.5 0.16 4.2 
5 
5 Lab 0.057 12.2 0.09 7.2 
5 Before  0.052 13.3 0.10 6.8 
5 After  0.054 12.7 0.12 5.6 
6 
6 Lab 0.066 10.4 0.20 3.5 
6 Before  0.058 11.9 0.16 4.2 
6 After  0.056 12.3 0.16 4.2 
Experiments were performed as per protocol outlined in the Methods section. Each set of clinical 
samples was performed on a different day with different donor neutrophils, but with the same lab 
strain. Calculations were done as described above and all the experiments met the condition for the 
method and it was confirmed by fitting a linear line in a semi-log graph.  
 
 
Table 8. Average rates of phagocytosis and killing of 6 before and after clinical isolates of S. 
aureus and laboratory strain 
Sample 
Phagocytosis Killing 
kp (min−1) SD kk (min−1)  (SD)  
Lab 0.065  0.010 0.15     (0.051) 
Before  0.059 0.006 0.15     (0.022) 
After  0.056 0.006 0.16     (0.019) 
Experiments were performed as per protocol outlined in the Methods section. The mean of six 




3.4. Preliminary investigation of whether exposure to sub-lethal 
HOCl could make S. aureus more resistant to a second exposure 
Previously, I had observed that when I performed the one-step neutrophil killing, 
not all of the S. aureus were killed by the end of the 40-minute killing experiment. 
When left overnight, more bacteria were present than at the start (result not 
shown). It was not clear whether the bacteria that grew back were from the inside 
of the phagosome or were extracellular bacteria that were not phagocytosed. 
Further experiments were performed with the two-step assay to determine if 
bacteria survive inside the phagosome. For this experiment I removed 
extracellular bacteria by doing a low speed spin, then analysed the viability of the 
remaining intracellular bacteria by colony counting. Samples were taken at 
intervals of up to 24 hours (Figure 13). The colony-forming units were of control 
(bacteria alone at 0 minutes). The viable bacteria, expressed as a percentage of the 
bacteria added (zero time) at 30 minutes were 9%, before dropping to about 4% 
for the next 1–2 hours. This suggested that some bacteria do survive inside the 
phagosome for a long time, despite the toxic conditions, and begin to multiply. This 
might have been due to survival gene expression when exposed to neutrophil 
killing reagents such as HOCl. Therefore, I wanted to determine whether exposure 
of S. aureus to sub-lethal concentrations of HOCl would induce potential survival 
genes, making them more resistant to subsequent dosed of HOCl.  
First, it was attempted to establish a sub-lethal dose of HOCl (Figure 14) by 
treating 108 S. aureus with different amounts of HOCl and measuring viable 
bacteria by colony counting. Total bacterial killing was observed at 10 nMoles/108 
bacteria and more than half were killed on exposure to 2.5 nMoles HOCl. HOCl is 
very reactive and at this low concentration reactions with traces of contaminants 
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can introduce large errors. Therefore, I used ten times more bacteria and increased 
the amount of HOCl ten-fold as well. Complete killing of S. aureus was observed 
with 120 nMoles HOCl (Figure 15). 25 nMoles HOCl showed 93% bacterial survival 
and 70% survival was seen at 50 nMoles HOCl. Therefore, the sub-lethal dose was 
chosen to be 35 nMoles/109 bacteria with around 90% viable bacteria (Figure 15).  
 
 
Figure 13. Analysis of survival of intracellular S. aureus after ingestion by neutrophils. 
S. aureus 108 cells/mL were opsonised for 20 minutes in 10% autologous serum before addition to 
neutrophils (10:1 ratio bacteria to neutrophil) followed by incubation at 37°C with gentle rotation 
(6 rpm). Samples were taken at 0.5, 1, 2, 3, and 24 hours. The bacteria in neutrophils were pelleted 
down with a low speed spin followed by three washes in PBS to remove extracellular bacteria, 
which were discarded. Neutrophils were then lysed to release the intracellular bacteria, which 





Figure 14. HOCl killing of S.aureus. 
S. aureus at 108 cells/mL were treated with varying amounts of HOCl (0, 2.5, 5, 10, 20, 30 nMoles) 
for 15 minutes and viable bacteria were determined by colony counting and expressed as a 




Figure 15. Determination of sub-lethal dose of HOCl for S. aureus. 
S. aureus at 109 cells were treated with varying amounts of HOCl, (0, 25, 50, 77,100, 125, 150 
nMoles) for 15 minutes and viable bacteria were determined by colony counting and expressed as a 





3.4.1. Effect of a sub-lethal dose of HOCl on S. aureus viability when given a 
second dose of HOCl. 
The hypothesis was that giving the bacteria a first hit with 35 nMoles would induce 
survival genes and they would be resistant to killing by a second hit, compared to 
those receiving no first hit.  
The bacteria were either untreated or given a first hit of 35 nmoles (pre-treated) 
HOCl then incubated for 30 minutes to give them time to induce any survival 
genes. They were then given a second hit of varying HOCl amounts and viable 
bacteria were measured after a further 15 minutes. The result in Figure 16 
indicated that was no difference in the concentration dependence between 
untreated bacteria and bacteria that were pre-treated. The majority of killing 
occurred when treated with 150 nMoles HOCl, viability for both around were 
around 10% which is the same as in Figure 15. Being pre-treated had no advantage 
for viability of bacteria when they were given a second hit of varying amounts of 
HOCl. However, if total exposure to HOCl is considered, there may be a difference. 
For example, when bacteria were pre-treated and exposed to a second dose of 50 
nMoles, which adds the total amount of HOCl to 85 (30+50) nMoles, the decrease 
in viability was only around 10% compared no first treatment + a second dose of 
50 nmoles. That means there is no significant loss of S. aureus in cumulative 
dosage. This is similar for all the other amounts of HOCl. On average, there was 
only about 10% decrease in bacterial viability when they received both hits 
compared to receiving just the first hit. Although this result may suggest that there 
might be a protection induced by S. aureus when they receive a pre-treatment with 
a sub-lethal dose of HOCl compared to no pre-treatment, however, a clear 
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conclusion cannot be drawn and the experiment needs to be explored further 
before extending the application to investigate neutrophils. 
 
 
Figure 16. Killing of S. aureus. 
S. aureus (109 in 1 mL) by HOCl. For every concentration of HOCl two tubes of bacteria at 109 cells 
were prepared where one tube was untreated for 30 min but received the second hit (blue line) and 
the other tube was pre-treated for 30 min as well as the second hit (red line) and incubated for a 
further 15 minutes. Reaction was stopped by addition of 100 μM methionine and viable bacteria 
were determined by colony counting and expressed as a percentage of untreated bacteria (S. aureus 




Section 4 – Discussion  
The main aim of this study was to compare the ability of neutrophils to kill S. 
aureus under standard conditions, in serum from healthy individuals, and in serum 
rich in inflammatory cytokines obtained from sepsis patients. Bacteria were pre-
treated in either healthy serum or sepsis serum and then incubated with 
neutrophils and samples were taken at appropriate times. My results indicated 
that there were no significant differences between neutrophil killing of S. aureus in 
normal serum to that in sepsis serum and that neutrophils kill S. aureus in sepsis 
serum just as well as they do in normal healthy serum. I also aimed to compare 
neutrophil killing of clinical strains of S. aureus isolated from sepsis patients before 
antibiotic treatment with isolates obtained taken after treatment. I wanted to 
determine whether there was a difference in neutrophil killing of the before and 
after treatment isolates as well as whether these were different to neutrophil 
killing of the lab strain of S. aureus. Results indicated that there was no difference. 
Finally, I looked at survival of bacteria after they received a sub-lethal dose of HOCl 
as a pilot study for a subsequent look at survival in neutrophils.  
4.1 Establishing methods 
First of all, it was important to adapt methods previously established in the lab for 
my purpose of comparing neutrophil killing of S. aureus in healthy and sepsis 
serum. I started with the one-step assay that measures a composite rate of 
phagocytosis and killing and the neutrophils are not separated from the 
undigested bacteria. The composite rate of phagocytosis and killing was measured 
and was calculated to be 0.0372 mins−1 and t1/2 = 20 mins.  
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The established method in our lab involves using 10% serum, however, I adapted 
this method in order to use 50% serum rather than 10% as I wanted the maximum 
amount of serum so that I could see the effect of any proinflammatory cytokines on 
neutrophil killing of S. aureus. Serum is plasma with fibrinogen and clotting factors 
removed and makes up about 55–60% of the blood volume (89). The reason serum 
is used instead of plasma is because S. aureus clumps in plasma. I tested this using 
10% healthy plasma and found bacteria clumped both during the opsonisation 
period and during incubation with neutrophils (data not shown). I tried to resolve 
it by vortexing the bacteria vigorously, but with no success. The reason for 
clumping is due to fibrinogen, which makes the majority of plasma protein (90), 
and S. aureus has many fibrinogen-binding proteins, such as coagulase (Coa) and 
fibrinogen-binding protein (Fbp). These proteins initiate clumping by binding to 
fibrinogen (91). Clumping by S. aureus is known to be used in order to decrease 
susceptibly towards the host immune defence system, such phagocytosis by 
neutrophils (92). Therefore, all the experiments were continued in serum rather 
than plasma.  
I wanted to test my sepsis serum samples with this assay containing 50% (rather 
than the standard 10%) serum, in order to maximize any effect of inflammatory 
components in the sepsis blood, by having minimal dilution. Before analysing the 
sepsis samples, I wanted to find out whether the composite rate of phagocytosis 
and killing was similar when using 50% serum compared to 10%. The result 
obtained showed that the standard protocol could be used with the higher serum 
concentration and with serum from healthy donors, since killing occurred at 
comparable rates under the two conditions. However, when I tried to test whether 
the killing mechanism was oxidative, the effect of DPI, as an inhibitor of the NADPH 
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oxidase was checked on neutrophil killing of S. aureus. The result indicated that the 
percentage of viable bacteria in the presence of 10 µM DPI was much lower in 50% 
serum (68% viable bacteria) compared to 94% viable in 10% serum. As a result, I 
tried a higher concentration of 50µM DPI, but no significant difference was found 
between 10µM and 50µM. Therefore, I tried 100µM concentration of DPI which 
resulted in 79% bacterial viability, slightly higher than the percentage viable with 
10µM and 50µM DPI but not significantly different. Even though, it was not 
comparable to that observed with 10% serum as it as was significantly less, it was 
similar to what was previously shown in the lab(84).The reason that a higher 
concentration of serum prevented the effectiveness of DPI was probably because 
of the proteins present in the serum binding to DPI. Previously, studies in our lab 
used 10% serum with 10µM DPI (84), which is a lower concentration of serum and 
DPI, and found that the killing of S. aureus was inhibited by 77% with 10uM. As 
expected, I found killing in this system is mainly oxidative. and MPO dependent.  
A limitation of the one-step assay is that it does not distinguish between 
phagocytosis and killing rates. Also, there is inherent variability in results using 
this assay, because of the plate-counting method used. This is decreased by doing 
four replicates. For each experiment performed, the starting of bacteria alone was 
different each time and variations in starting number will likely be due to 
differences in the growth of the overnight bacterial culture from day-to-day. For 
the majority of the experiments I have shown the percentage of viable bacteria 
rather the CFU number.  
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4.2 Comparing neutrophil killing of S. aureus in healthy and sepsis 
serum 
As explained in Section 1, neutrophils are the first line of defence in the human 
immune system and they generate ROS as part of their arsenal for killing microbes. 
Incapacity to do this is linked to life-threatening infections. Neutrophil oxidants 
are also involved in tissue injury related with inflammatory states such as sepsis. 
The majority of killing assays have generally been carried out in standard 
laboratory buffers with sufficient serum for the opsonisation process. Therefore, I 
wanted to find out whether the cytokines that become elevated during sepsis could 
affect the ability of the neutrophils to kill, compared to healthy serum. Thus I 
wanted to optimize the amount of serum in the assay to observe this effect. I 
wanted to see if ability to kill bacteria altered in sepsis, which could be due to 
alterations in neutrophil function, because of the constituents of serum such as 
cytokines like TNFα, known to prime the oxidative burst which could cause 
neutrophils to kill bacteria more efficiently.  
Samples were collected from patients who were admitted to hospital showing 
signs of sepsis such as elevated heart rate, high temperature and high serum C-
reactive proteins (CRP). CRP is an acute phase protein released by the liver in the 
course of inflammation. While its role throughout the acute inflammation is not 
completely clear (93), it is known to help recognize foreign microorganisms by 
binding to phosphocholinesterase, as well as having proinflammatory effects such 
as inducing inflammatory cytokines in phagocytic cells (94). Synthesis of CRP takes 
place in the liver and it is initiated by the proinflammatory cytokine, IL-6 (93). The 
normal plasma levels of CRP in healthy individuals are defined as <10mg/L and the 
concentration of CRP in the blood can rise up to 1000-fold when liver cells are 
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stimulated by pro-inflammatory cytokines (94). Because of its sudden rise during 
inflammation, CRP is used as a biomarker of sepsis and studies carried out by 
Keshet and colleagues found that very high plasma CRP levels of >200 mg/L was 
indicative of sepsis infection (95).  
All the patients who provided samples presented with high levels of CRP, ranging 
between 109 to 373 mg/mL, and other evidence of sepsis. As a result, I expected 
high levels of pro-inflammatory cytokines such as TNFα in the patient serum. 
Therefore, I wanted to examine whether pre-incubation of neutrophils in 
proinflammatory high sepsis serum would prime neutrophils and lead them to 
generate more superoxide when with fMLP stimulation. Priming is a procedure 
that results in a significant rise to the responsiveness of neutrophils towards 
phagocytosis of invading microorganisms, including enhancement of their 
oxidative burst (96). TNFα is one of the proinflammatory cytokines that induces 
priming (85). In my experiment, I measured cytochrome c reduction and the result 
showed that when neutrophils pre-treated with sepsis serum, stimulating them 
with fMLP led to significantly more superoxide production (11.7 ± 1.5) compared 
to those incubated in buffer containing healthy serum (6.4 ± 0.6) p = 0.0305 or in 
buffer alone (Table 5). This is consistent with the neutrophils being primed by pro-
inflammatory cytokines in the sepsis serum. Addition of TNF had no significant 
effect on superoxide production in the presence of sepsis serum. Moreover, 
neutrophils incubated in buffer alone and primed with TNF produced 
significantly increased superoxide due to stimulation with fMLP, but in contrast 
neutrophils incubated in healthy serum and primed with TNF did not show 
increased superoxide production. The explanation for the latter observation is 
uncertain, but one possibility is that constituent(s) of healthy serum such as anti-
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inflammatory cytokines such as IL-10 (97), prevented an increased superoxide 
production.  
The enhanced superoxide production is consistent with there being elevated pro-
inflammatory cytokines in sepsis serum. Therefore, I wanted to find out whether 
neutrophil killing of S. aureus is different in sepsis serum compared to normal 
healthy serum. Using the one-step killing assay to test this question I found that S. 
aureus killing by neutrophils incubated in the presence of sepsis serum was not 
significantly different from killing by neutrophils incubated with healthy serum. 
This indicated that neutrophils in sepsis serum kill S. aureus just as well as in 
healthy serum. I saw day-to-day variability between different neutrophils but 
comparison with same cells showed no difference and the result showed good 
exponential loss. I predicted that since there were high amounts of pro-
inflammatory cytokines present in sepsis serum, the killing would be faster as the 
neutrophils have been exposed to these reagents, which would prime them and 
subsequently enable them to kill bacteria faster than those in healthy serum. 
However, the result did not support that. Controls in this experiment included 
growing bacteria alone in media containing healthy or sepsis serum in the absence 
of neutrophil, to account for the growth of bacteria, as well as to check for any 
antibiotic activity which could have been present in sepsis serum. This was done 
for every experiment and bacteria alone grew similarly in both media, confirming 
there no antibiotic in sepsis serum.  
The effect of DPI was measured for neutrophils incubated in either healthy or 
sepsis serum to see if there was a different oxidative killing mechanism and the 
result indicated that there were no significant differences between the percentage 
of viable bacteria in healthy compared to sepsis serum, which meant that 
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neutrophil in both conditions kills S. aureus by oxidative mechanism because the 
DPI inhibitor can inhibit it.  
Since the one-step assay result showed no difference between the composite rate 
of killing and phagocytosis of S. aureus by neutrophils incubated in either sepsis 
serum or healthy serum, the phagocytosis experiment was carried out to see if 
there was a difference in the rate of phagocytosis of S. aureus by neutrophils in 
these different media, to check if perhaps the difference in the rate of phagocytosis 
was obscuring a difference in the killing rate. Again, no significant difference was 
found in the rate of phagocytosis between them.  
Even though the cytochrome c experiment indicated that neutrophils pre-treated 
in sepsis serum produced more superoxide than in healthy serum, I found that this 
was not associated with a significant difference in the rate of killing of S. aureus 
under my conditions. Even though I found killing to be predominantly oxidative, 
this suggests that neutrophils kill bacteria in sepsis serum just as well as in healthy 
serum. 
Next, I tried to explore neutrophil killing of a gram-negative bacteria, E. coli, to see 
if it differed in healthy compared to sepsis serum. First of all, I faced the problem of 
bacteria not surviving in pH 11 water, which we used to lyse neutrophils to release 
intracellular bacteria. The second problem was that bacteria were clumping during 
the opsonisation period, making it hard to quantify how many bacteria were being 
added to stimulate the neutrophils. Solving the declumping problem took a 
considerable amount of time before realising that they would clump again once 
added to the neutrophils. It was not appropriate to use the same declumping 
approach at this stage because it would have caused the neutrophils to lyse and 
release intracellular bacteria, thus giving false results for phagocytosis and killing. 
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While it would have been interesting to find out whether neutrophil killing of a 
different bacteria was different in healthy and in sepsis serum, time did not permit 
me to overcome this problem and explore further. 
4.3 Neutrophil killing of pathogenic S. aureus (clinical isolates) 
compared to the lab strain S. aureus 
The aim of this part of the thesis was to look at the neutrophil difference between 
the phagocytosis and the killing rates of clinical isolates of S. aureus in the 
laboratory strain. It is known that bacteria can survive antibiotic treatments and 
proliferate in immune cells such as KCs in the liver, eventually disseminating to 
other organs, successfully causing subsequent infections (74). To protect 
themselves, bacteria have evolved many mechanisms. It has been noted that 
carotenoid pigments of S. aureus are involved in bacterial protection against 
photosensitization and desiccation (98). Additionally, most S. aureus contain a 
range of different enzymes used to resist the mechanism of oxidative killing by 
neutrophil. The enzymes include superoxide dismutase, catalase, peroxiredoxins 
and more, used to detoxify the effect of reactive oxygen and nitrogen intermediates 
(98).  
Clinical isolates were provided by the Canterbury Health Laboratories and samples 
were collected from patients who were blood-culture positive for S. aureus (before 
samples) after an average of 2.4 days after antibiotic treatment. A positive blood 
culture at the latter time is a poor prognostic indicator. 
The bacteria were stored at −80°C on sepharose beads before experimentation. 
The bacteria were then grown on blood agar and routinely sub-cultured. The two-
step assay was used to measure the rates of neutrophil phagocytosis and killing of 
clinical isolates and the normal lab strain S. aureus. The advantage of using the 
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two-step method for this assay was that it measured rates of phagocytosis and 
killing separately, as opposed to the one-step method which gives a composite rate 
of phagocytosis and killing. I was interested in comparing the rate constants 
between the lab strain and the before-strain and subsequently rates between 
before- and after-samples. The reason that I compared the lab strain to the before-
sample was to see the if there was any pre-existing resistance that would mean a 
better survival rate of neutrophil killing compared to the lab strain. The result 
indicated that there were no significant differences in the phagocytosis or the 
killing rate between the lab strain and the before sample. I also compared the 
before-sample to after-sample in order to check if there was a further development 
of resistance during the infection and treatment. However, the results showed no 
significant differences between before- and after-samples.  
In order to be able to use the established method for calculating the rate of 
phagocytosis and killing, phagocytosis should follow first order kinetics. A linear 
relationship on a semi-log graph would confirm this. However, in the experiment 
conducted here, only a reasonable linear relationship was seen, due to a rapid 
initial loss of extracellular bacteria. This was true for all the experiments including 
the lab strain and before- and after-samples. However, approximate rates could be 
calculated and it was clear from these that there were no differences between the 
clinical isolates and the lab strain.  
According to the result obtained, it cannot be excluded that bacteria are able to 
induce genes for protection against oxidative killing in neutrophils when they are 
exposed to immune cells. However, once they are isolated from the blood, they 
might have reverted back to normal expression before testing. This could have 
resulted by sub-culturing them in the lab before experiments were done and a way 
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to test this is by using fresh bacteria straight out of the −80°C without exposing 
them to normal growth condition. 
4.4 Effect of a sub-lethal dose of hypochlorous acid (HOCl) on S. 
aureus viability when given a second dose of HOCl 
Hypochlorous acid remains one of the powerful oxidants which interacts with 
most of the cellular macromolecules (77). It is a reactive oxidant, used by the 
neutrophils to kill invading microorganisms. Previously, it was shown that when a 
one-step neutrophil killing assay was performed over 40 minutes, there was no 
complete killing observed during this time, and when samples were left incubating 
over-night there were still viable bacteria observed. However, it was not clear as to 
whether the viable bacteria were from intracellular or extracellular that had never 
been phagocytosed. To address this question, a two- step killing method was 
applied where the intracellular would be separated form extracellular bacteria by 
differential centrifugation. The bacteria were incubated over 24 hours and samples 
were taken over the time period. The result indicated that intracellular bacteria 
viability decreased to 9% by one hour and by 2–3 hours it increased back to 13% 
viable. This suggested that there might be expression of survival genes which 
protected them against killing in the phagosome. To address this, an experiment 
was designed to see the effect of survival gene expression by first exposing 
bacteria to a sub-lethal dose of HOCl, then later to higher concentrations.  
This experiment was performed in order to check if S. aureus pre-treated with a 
sub-lethal dose of HOCl would survive better than those which had not received a 
pre-treatment when exposed to a higher concentration of HOCl. It was 
hypothesized that bacteria that were incubated with HOCl for a certain time could 
induce survival genes that would give resistance upon exposure. This was a pilot 
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study that could subsequently be applied to examining if the same mechanism 
operated for neutrophils exposed to HOCl in neutrophil phagosomes. 
First, experiments were done to determine the effect of HOCl concentrations on the 
survival of S. aureus and the result indicated complete killing was observed when 
108 cells were treated with 10 nMoles HOCl. In order to prevent any errors with 
small amounts of HOCl, it was decided to use ten times more bacteria and ten times 
more HOCl to get a measurement of HOCl. 35 nMoles HOCl per 109 S. aureus were 
determined to be a sub-lethal dose.  
Bacteria were then either pre-treated with 35 nMoles HOCl or not pre-treated for 
30 minutes. They were then exposed to varying concentrations of HOCl for a 
further 15 minutes to see the killing effect. The result indicated that there was no 
difference in the rate of killing by concentration dependence. As the concentration 
is increased, the rate of survival for S. aureus treated in both conditions decreased. 
That meant that pre-incubated bacteria were killed at the same rate as those that 
received no pre-incubation with the sub-lethal dose. The majority of killing was 
observed with exposure to 150 nMoles. However, if the result is considered in a 
different way, those that had been pre-treated received a higher cumulative dose 
of HOCl, yet were no more susceptible. This means that, for example, when 
bacteria were pre-treated and exposed to a second dose of 50 nMoles, which adds 
the total amount of HOCl to 85 (30+50) nMoles, the decrease in viability was only 
around 10% compared to no first treatment + a second dose of 50 nMoles. This 
means that there might have been genes induced in response of the oxidative 
stress that HOCl exerted and that protected the bacteria against a second hit. It has 
been noted before that a sub-lethal dose of HOCl can activate transcription factors, 
leading to upregulation of the expression of survival genes, allowing the bacteria to 
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resist higher doses of HOCl (77). However, more work is needed to determine 
whether this is the case with S. aureus in my experimental system. 
4.5 Summary and future work 
In summary I have successfully adapted the one-step method to test the effect of 
media on neutrophil killing of S. aureus. I have shown that there is significantly 
higher superoxide production by neutrophils in the presence of sepsis serum 
compared to neutrophils pre-treated in healthy serum. I have shown that the 
composite rate of phagocytosis and killing is the same between healthy and sepsis 
serum and the rates of phagocytosis were also the same. However, there were a 
couple of outliers within the seven sepsis samples I tested and further experiments 
with more samples are needed to improve the conclusion.  
I have also shown that the phagocytosis and killing rate for the clinical isolates and 
the lab strain S. aureus were the same. However, experiments were performed only 
once with each sample and therefore this experiment needs further investigation.  
I have also looked at a pilot study to see the effect of sub-lethal doses of HOCl on 
the survival of bacteria with higher concentrations of HOCl. Further 
experimentation is needed to characterize whether there is any adaptation with 
reagent HOCl, and then to investigate whether such a mechanism occurs with 
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